Ingrid A. Mayer, MD, on New Therapies for Hormone-Sensitive Advanced Breast Cancer
2015 NCCN Annual ConferenceIngrid A. Mayer, MD, of the Vanderbilt-Ingram Cancer Center, discusses the evolution of endocrine therapy for metastatic breast cancer.
Ingrid A. Mayer, MD, of the Vanderbilt-Ingram Cancer Center, discusses the evolution of endocrine therapy for metastatic breast cancer.
Leora Horn, MD, MSc, of the Vanderbilt-Ingram Cancer Center, discusses the range of treatment options for people with lung cancer, including third generation inhibitors, and the key clinical trials studying alternatives for patients with acquired resistance.
Samuel M. Silver, MD, PhD, of the University of Michigan Comprehensive Cancer Center, and David S. Ettinger, MD, of The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, discuss the evolution of the NCCN Guidelines, the importance of including palliative care and survivorship recommendations, and the use of the guidelines in community practices.
Andrew J. Armstrong, MD, ScM, of Duke Cancer Institute, discusses the recent practice-changing landmark studies that showed significant increases in survival for men with castration-resistant prostate cancer and led to updates in the NCCN Guidelines for this disease.
Robert W. Carlson, MD, Chief Executive Officer, National Comprehensive Cancer Network, and William J. Gradishar, MD, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discuss the evolution of the breast cancer guidelines, the inclusion of varied fields––such as plastic surgery, pathology, patient advocacy, and radiation–– and new treatment changes.
Anthony J. Olszanski, RPh, MD, of the Fox Chase Cancer Center, discusses the advances in immunotherapy generally and for melanoma in particular.